(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)
* Facebook, Amazon, Alphabet tumble on fears of regulatory risks
* U.S. manufacturing activity unexpectedly slows last month
* Healthcare boosted by Amgen, Gilead, Merck
* Dow up 0.02%, S&P 500 down 0.28%, Nasdaq off 1.61% (Updates to close)
By Sinéad Carew
New York June 3 (Reuters) - The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators.
While the sell-off in the internet heavyweights was the biggest drag on the Nasdaq, the index has been falling steadily since its May 3 record closing high as investors worried about slowing global growth amid an escalating U.S.-China trade war.
The S&P 500 had a volatile session and ended the day down 0.3 percent, but the Dow Jones Industrial Average ended the session virtually unchanged.
“The slump has been concurrent with fears of slowing global growth,” said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama. He noted that weak manufacturing data around the world appeared to be confirming those fears.
“Right now Nasdaq is basically where we were at the lows in March. This is an important level to hold here. If we break below that, we fall further. Tomorrow will be an important day to see if the trend continues lower.”
The Dow Jones Industrial Average rose 4.74 points, or 0.02%, to 24,819.78, the S&P 500 lost 7.61 points, or 0.28%, to 2,744.45 and the Nasdaq Composite dropped 120.13 points, or 1.61%, to 7,333.02 which was 10.2% lower than its May 3 close.
A correction is defined as a 10 percent drop from the most recent 52-week high.
The benchmark S&P 500 swung in and out of negative territory during the day as investors monitored the latest comments around the U.S. trade battles with both China and Mexico, as well as U.S. President Donald Trump’s decision on Friday to end preferential trade treatment for India.
“We’re surprised the market didn’t take a sourer tone today not only with China digging in, the Mexico headlines and the U.S. revoking India’s status as a developing country,” said John Augustine, chief investment officer at Huntington National Bank in Columbus, Ohio. He also cited weak manufacturing data.
“Investors must be thinking in some form that this is as bad as the headlines and economic reports are going to get this week,” Augustine said.
An ISM survey showed U.S. manufacturing growth unexpectedly slowed in May, driving demand for the safety of government bonds. Two-year yields hit their lowest since September 2017 on growing conviction that the Federal Reserve will start cutting interest rates to stave off a recession.
High-profile internet stocks dominated trading, with Facebook Inc closing down 7.5% after the Wall Street Journal reported that the Federal Trade Commission has secured the right to examine how the social media company’s practices affect digital competition. The stock was on pace for its biggest one-day drop since July 26.
Alphabet Inc tumbled 6% after sources told Reuters the U.S. Justice Department is preparing an investigation to determine if the Google parent broke antitrust laws. Amazon.com fell 4.6% on a report that the e-commerce giant could be put under the watch of the FTC.
The communication services sector, which includes Google and Facebook, closed down 2.8%, the biggest drop of the S&P’s 11 major sectors, while Amazon shares helped pull the consumer discretionary sector down 1.2%.
The S&P materials sector was the biggest percentage gainer of the S&P’s major sectors, with a 3.4% advance. Dupont’s 11.5% gain accounted for roughly half of the sector’s rise in the first trading session after it spun off its Corteva Inc agriculture business.
Healthcare was one bright spot for the Nasdaq, with the Nasdaq biotech index climbing 1.2%, helped by shares of companies including Amgen Inc and Gilead. Amgen and Merck & Co reported positive drug data at the annual American Society of Clinical Oncology meeting in Chicago.
Amgen jumped 3.4% after its drug showed a high response rate in a small lung and colon cancer trial, while Merck rose 1.3% after data showed nearly a quarter of patients who received immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years.
The S&P 500 posted 17 new 52-week highs and 21 new lows; the Nasdaq Composite recorded 24 new highs and 170 new lows.
On U.S. exchanges 8.34 billion shares changed hands compared with the 7.11 billion average for the last 20 sessions. (Reporting by Medha Singh, Amy Caren Daniel and Shreyashi Sanyal in Bengaluru Editing by Bernard Orr, Maju Samuel, Steve Orlofsky and Dan Grebler)